1. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G,
et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182–2194.
2. Nagar S, Blanchard RL. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 2006;38:393–409.
3. Karas S, Innocenti F. All you need to know about
UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide. JCO Oncol Pract 2022;18:270–277.
4. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M,
et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382–1388.
5. Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K,
et al.
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 2009;14:136–142.
6. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H,
et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921–6926.
7. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H,
et al.
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004;75:501–515.
9. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human
UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002;62:608–617.
10. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005;15:295–301.
11. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE,
et al. Comprehensive analysis of
UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006;24:2237–2244.
12. Gao J, Zhou J, Li Y, Peng Z, Li Y, Wang X,
et al. Associations between
UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Med Oncol 2013;30:630.
13. Park SR, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH,
et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol 2011;22:890–896.
14. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
16. Im CK, Rha SY, Jeung HC, Ahn JB, Shin SJ, Noh SH,
et al. A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. Am J Clin Oncol 2010;33:56–60.
17. Yea SS, Lee SS, Kim WY, Liu KH, Kim H, Shon JH,
et al. Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 2008;30:23–34.
18. Kim JO, Shin JY, Lee MA, Chae HS, Lee CH, Roh JS, et al. Genetic polymorphisms of UGT1A and their association with clinical factors in healthy Koreans. Genomics Inform 2007;5.4:161–167.
19. Oh SY, Kim YB, Chun MS, Suh KW. The efficacy of
UGT1A1 polymorphism in chemoradiation therapy using irinotecan in patients with locally advanced rectal cancer. J Korean Soc Coloproctol 2007;23:344–349.
21. Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T,
et al. Close association of
UGT1A9 IVS1+399C>T with
UGT1A1*28,
*6, or
*60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos 2009;37:272–276.
22. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P,
et al.
UGT1A7 and
UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226–1236.
23. Fujita K, Ando Y, Nagashima F, Yamamoto W, Eodo H, Araki K,
et al. Genetic linkage of
UGT1A7 and
UGT1A9 polymorphisms to
UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 2007;60:515–522.
24. Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K,
et al.
UGT1A1*6, 1A7*3, and
1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 2013;104:1662–1669.
25. Wang H, Bian T, Jin T, Chen Y, Lin A, Chen C. Association analysis of
UGT1A genotype and haplotype with SN-38 glucuronidation in human livers. Pharmacogenomics 2014;15:785–798.
26. Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T,
et al.
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007;25:2594–2600.